Oncology
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Ghaith Bakdash described how Microbiotica discovered a specific microbiome signature in patients responder to immune-oncology drugs such as anti-PD1 / PDL1 and developed a new bacterial consortium.
New research indicates that the tumor-resident microbiota can promote the formation of metastases as well as the survival of cancer cells during tumor progression.
Researchers have found that a specific microbial metabolite may boost the efficacy of anticancer therapy in people with TNBC. The findings could inform the development of improved treatments for TNBC.
New research investigates the role of lung microbiota in pediatric patients with lung infection or injury after bone marrow transplantation.
The findings could help to develop microbiota-based strategies to advance immunothery treatments for melanoma.
Researchers have found that combining a probiotic product with immunotherapy may boost anti-tumor responses in people with advanced kidney cancer.
Akkermansia can be used as a biomarker to identify who is likely to respond to treatment with immune checkpoint inhibitors. A new study published in Nature Medicine claims
A high-fiber diet may improve melanoma patients’ response to immunotherapy. A new study published in Science claims.
Lactobacillus reuteri can protect against colorectal cancer through reuterin, one of its metabolites. A new study published in Cencer Cell claims
